Total debt of only $2.9M against $1.2B in equity yields a near-zero debt-to-equity ratio, though the balance sheet appears vulnerable given cash of $191.5M against a $44.3M quarterly operating outflow and a -$312.1M accumulated deficit.
Oruka Therapeutics, Inc. (ORKA) balance sheet — 21-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 |
|---|
| Total Current Assets | 941.49M | 343.86M | 376.87M | 37.59M | 42.7M | 54.42M | 49.97M | 8.48M | 6.78M | 12.3M | 21.45M | 38.92M | 15.49M | 16.93M | 3.04M | 6.21M | 7.16M | 8.29M | 9.68M | 99.99M | 166.34M | 85.77M |
| Cash & Short-Term Investments | 920.28M | 337.04M | 375.65M | 37.43M | 42.45M | 53.36M | 49.07M | 8.36M | 6.61M | 11.75M | 21.16M | 38.8M | 15.35M | 16.76M | 2.92M | 5.94M | 7.03M | 7.76M | 7.74M | 97.57M | 153.13M | 70.34M |
| Cash Only | 191.52M | 46.94M | 61.58M | 37.43M | 42.45M | 53.36M | 49.07M | 8.36M | 6.61M | 8.7M | 7.4M | 38.8M | 15.35M | 16.76M | 2.92M | 5.94M | 7.03M | 7.76M | 7.74M | 32.06M | 60.34M | 37.76M |
| Short-Term Investments | 728.76M | 290.11M | 314.07M | 0 | 0 | 0 | 0 | 0 | 0 | 3.05M | 13.76M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 65.51M | 92.79M | 32.57M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 588K | 8.56M | 1.21M |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.58 | 803.51 | 808.36 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 6.81M | 1.22M | 161K | 254K | 1.06M | 897K | 117K | 169K | 547K | 282K | 114K | 134K | 169K | 125K | 269K | 137K | 522K | 1.94M | 1.83M | 4.65M | 1.96M |
| Total Non-Current Assets | 289.53M | 144.76M | 19.15M | 269K | 386K | 503K | 461K | 56K | 48K | 66K | 3.18M | 658K | 644K | 159K | 167K | 290K | 994K | 1.09M | 1.4M | 20.7M | 18.07M | 22.28M |
| Property, Plant & Equipment | 3.1M | 2.12M | 1.04M | 257K | 368K | 485K | 449K | 32K | 24K | 42K | 66K | 28K | 36K | 29K | 23K | 66K | 690K | 1.03M | 1.3M | 8.91M | 11.98M | 15.16M |
| Fixed Asset Turnover | 0.00x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.26x | 0.32x | 0.04x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.67M | 4.67M | 4.67M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 787.99M | 142.54M | 18.07M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.35M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6M | 0 | 0 |
| Other Non-Current Assets | 128K | 103K | 43K | 12K | 18K | 18K | 12K | 24K | 24K | 24K | 766K | 630K | 608K | 130K | 144K | 224K | 304K | 61K | 98K | 1.12M | 1.42M | 2.44M |
| Total Assets | 1.23B | 488.62M | 396.02M | 37.86M | 43.09M | 54.92M | 50.43M | 8.54M | 6.83M | 12.37M | 24.63M | 39.57M | 16.13M | 17.08M | 3.21M | 6.5M | 8.16M | 9.37M | 11.08M | 120.68M | 184.41M | 108.05M |
| Asset Turnover | 0.00x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.39x | 0.02x | 0.01x |
| Asset Growth % | 417.67% | 23.38% | 945.98% | -12.12% | -21.56% | 8.91% | 490.78% | 25.07% | -44.8% | -49.8% | -37.76% | 145.31% | -5.57% | 431.88% | -50.6% | -20.28% | -12.97% | -15.41% | -90.82% | -34.56% | 70.67% | - |
| Total Current Liabilities | 31.78M | 15.37M | 13.04M | 637K | 1.13M | 3.5M | 3.5M | 926K | 793K | 2.07M | 2.4M | 1.5M | 1.39M | 1.5M | 305K | 754K | 1.19M | 1.64M | 15.83M | 18.19M | 43.84M | 36.18M |
| Accounts Payable | 14.38M | 4.16M | 3.46M | 0 | 334K | 1.12M | 1.77M | 418K | 230K | 622K | 0 | 0 | 0 | 597K | 65K | 260K | 388K | 533K | 804K | 2.76M | 7.03M | 4.92M |
| Days Payables Outstanding | 16.88K | 18.27K | 46.8K | - | 1.07K | 4.48K | 6.96K | 1.71K | 3.82K | 8.41K | - | - | - | 8.38K | 551.74 | 32.53 | 418.99 | - | - | 429.96 | 805.94 | 31.07 |
| Short-Term Debt | 0 | 619K | 213K | 76K | 103K | 100K | 41K | 25K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12.3M | 0 | 3.66M | 8.29M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16K | 33K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 50K | 5.33M | 7.33M | 461K | 522K | 1.36M | 870K | 354K | 413K | 691K | 1.68M | 835K | 1.06M | 446K | 121K | 350K | 627K | 870K | 1.66M | 13.08M | 30.06M | 20.7M |
| Current Ratio | 29.62x | 22.37x | 28.89x | 59.01x | 37.72x | 15.56x | 14.28x | 9.16x | 8.55x | 5.94x | 8.95x | 25.88x | 11.16x | 11.27x | 9.98x | 8.24x | 6.02x | 5.04x | 0.61x | 5.50x | 3.79x | 2.37x |
| Quick Ratio | 29.62x | 22.37x | 28.89x | 59.01x | 37.72x | 15.56x | 14.28x | 9.16x | 8.55x | 5.94x | 8.95x | 25.88x | 11.16x | 11.27x | 9.98x | 8.24x | 6.02x | 5.04x | 0.61x | 5.50x | 3.79x | 2.37x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 2.09M | 1.31M | 755K | 204K | 280K | 383K | 409K | 0 | 0 | 20K | 39K | 0 | 3K | 1K | 0 | 16K | 195K | 316K | 562K | 34.84M | 70.72M | 15.1M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 19.07M | 3.78M |
| Capital Lease Obligations | 6.41M | 1.31M | 755K | 204K | 280K | 383K | 409K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20K | 39K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 132K | 13.18M | 125K | 359K |
| Total Liabilities | 33.88M | 16.69M | 13.8M | 841K | 1.41M | 3.88M | 3.91M | 926K | 793K | 2.09M | 2.44M | 1.5M | 1.39M | 1.5M | 305K | 770K | 1.39M | 1.96M | 16.39M | 53.02M | 114.56M | 51.28M |
| Total Debt | 2.93M | 1.93M | 968K | 280K | 383K | 483K | 450K | 25K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12.3M | 0 | 22.73M | 12.07M |
| Net Debt | -188.59M | -45M | -60.61M | -37.15M | -42.06M | -52.88M | -48.62M | -8.34M | -6.61M | -8.7M | -7.4M | -38.8M | -15.35M | -16.76M | -2.92M | -5.94M | -7.03M | -7.76M | 4.56M | -32.06M | -37.61M | -25.69M |
| Debt / Equity | 0.00x | 0.00x | 0.00x | 0.01x | 0.01x | 0.01x | 0.01x | 0.00x | - | - | - | - | - | - | - | - | - | - | - | - | 0.33x | 0.21x |
| Debt / EBITDA | -0.02x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 1.03x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | -56.03x | - | - | - | -1082.00x | -806.00x | - | - | - | - | - | - | -1439.00x | -1071.80x | -1051.50x | -60.72x | -108.16x | -118.43x | -224.81x | -70.05x |
| Total Equity | 1.2B | 471.93M | 382.22M | 37.02M | 41.67M | 51.04M | 46.52M | 7.61M | 6.03M | 10.28M | 22.19M | 38.07M | 14.74M | 15.58M | 2.91M | 5.73M | 6.77M | 7.41M | -5.31M | 67.66M | 69.84M | 56.76M |
| Equity Growth % | 427.18% | 23.47% | 932.47% | -11.17% | -18.36% | 9.72% | 511.31% | 26.16% | -41.29% | -53.7% | -41.7% | 158.26% | -5.39% | 435.98% | -49.28% | -15.34% | -8.65% | 239.51% | -107.85% | -3.13% | 23.04% | - |
| Book Value per Share | 16.72 | 10.35 | 22.77 | 2.57 | 2.89 | 3.67 | 9.88 | 69.12 | 94.08 | 212.76 | 528.71 | 1307.48 | 1087.17 | 2730.16 | 1977.55 | 5182.64 | 7221.28 | 9480.92 | -999999.00 | 230177.36 | 246298.69 | 249503.62 |
| Total Shareholders' Equity | 1.2B | 471.93M | 382.22M | 37.02M | 41.67M | 51.04M | 46.52M | 7.61M | 6.03M | 10.28M | 22.19M | 38.07M | 14.74M | 15.58M | 2.91M | 5.73M | 6.77M | 7.41M | -5.31M | 67.66M | 69.84M | 56.76M |
| Common Stock | 67K | 49K | 37K | 14K | 14K | 14K | 10K | 2K | 14K | 12K | 9K | 9K | 21K | 16K | 3K | 12K | 9K | 8K | 1K | 53K | 53K | 44K |
| Retained Earnings | -312.15M | -189.16M | -83.72M | -188.74M | -183.4M | -173.48M | -154.15M | -144.42M | -138.93M | -131M | -112.51M | -96.07M | -84.62M | -74.93M | -67.99M | -63.67M | -58.31M | -49.89M | -40.75M | -470.51M | -458.21M | -327.66M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -5.04M | 546K | -41K | 0 | 0 | 0 | 0 | 0 | 0 | -2K | -19K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 49K | 10K | -250K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying ORKA stock.
As of 2025, Oruka Therapeutics, Inc. (ORKA) had total assets of $488.6M including $343.9M in current assets.
Oruka Therapeutics, Inc. (ORKA) carries total debt of $1.9M, offset by $337.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Oruka Therapeutics, Inc. (ORKA) has total shareholders' equity (book value) of $471.9M ($10.35 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Oruka Therapeutics, Inc. (ORKA) reported a current ratio of 22.37x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Dilutive financing dependence risk
Balance Sheet Expands Through Equity Raises
According to recent SEC filings, ORKA's total assets rose from roughly $33.8M in 2024Q2 to $1.2B in 2026Q3, a pattern driven almost entirely by equity capital rather than operating earnings, which carry no contribution given the company's pre-revenue status.
The equity base has grown from $32.6M to about $1.2B while retained earnings deepened from -$193.4M to -$312.1M, which suggests the expansion reflects capital injections rather than accumulated profitability. Investors should view the rapid asset growth as a function of financing activity, and the magnitude of the 2026Q2 jump warrants further investigation into the terms and dilution associated with those raises.
Cash Buffer Thin Against Quarterly Burn
Based on reported figures, ORKA held approximately $46.9M in cash at 2025Q4 and $191.5M at 2026Q3, against a latest quarterly operating cash outflow of roughly $44.3M, leaving the buffer sensitive to the timing of subsequent financing.
The current ratio of 29.62 in 2026Q3 appears strong on its face, but it reflects a near-zero liability base rather than abundant operating resilience. Measured against the most recent quarterly burn, the reported cash position suggests only a few quarters of runway, which may indicate that the company's ability to reach its next clinical readout depends on continued access to capital markets.
Negligible Debt Keeps Leverage Minimal
As reported in financial statements, ORKA's total debt stood at $2.9M in 2026Q3 against $1.2B in equity, producing a debt-to-equity ratio near zero and placing leverage risk well outside the company's current capital structure concerns.
The minimal debt load means refinancing risk is effectively data unavailable as a meaningful pressure point at present. The more relevant balance sheet exposure is the reliance on equity financing, which may dilute existing holders as the company funds clinical spend rather than borrowing against future cash flows.
Asset-Light Profile Concentrates in Cash
Based on reported figures, ORKA's PPE net stood at only $3.1M in 2026Q3 and goodwill was recorded at zero, indicating that nearly all reported assets consist of cash and short-term holdings rather than productive physical infrastructure.
This asset mix is consistent with an outsourced clinical-stage model in which manufacturing and discovery are handled externally, reducing fixed capital requirements. The absence of goodwill removes impairment risk from the balance sheet, though the lack of tangible operating assets means value rests almost entirely on the clinical pipeline rather than on hard collateral.
Accumulated Deficit Widens Despite Equity Growth
According to recent SEC filings, ORKA's retained earnings deficit widened from -$193.4M in 2024Q2 to -$312.1M in 2026Q3, even as paid-in capital expanded substantially, indicating that equity raises have been absorbed by operating losses.
Stock-based compensation of $9.1M in 2026Q3 contributes to the equity base through non-cash charges, which may partially inflate the apparent book value relative to cash generated. Shareholders should monitor how the continued issuance of shares to fund clinical programs affects per-share value, as the deficit trend suggests dilution is a recurring feature of the capital structure.
Asset Growth Masks Shrinking Runway
Based on reported figures, the headline $1.2B asset base in 2026Q3 may overstate near-term financial flexibility, since reported cash of $191.5M compares against a quarterly operating outflow near $44.3M and the cumulative burn across ten quarters exceeds $260M.
The gap between total assets and cash suggests much of the reported balance sheet value may not be readily available to fund operations, which warrants monitoring of the composition of non-cash assets. Investors should be cautious about interpreting the headline equity figure as evidence of durable capital strength, since the company's cash-based runway appears materially shorter than the asset total implies.